Male Yeast Infections In Immunocompromised Patients (HIV, Chemotherapy)
Published on: December 16, 2025
Male Yeast Infections in Immunocompromised Patients featured image

Introduction 

Yeast infections are often considered a female issue, but men also suffer from yeast infections.

An excessively large amount of Candida albican fungus on the penis results in candidal balanitis, a disease that is associated with irritation of the penis but can also be accompanied by painful inflammation.1,2

In most healthy men, the infections are of a short-lived nature, and they respond to the topical treatment.

Nonetheless, Candida may be more common, more intense, and slower to resolve in individuals whose immune systems are compromised, such as by HIV or chemotherapy.3,4

That alters the way the infection is handled by doctors as well as the day-to-day life of patients.

This article discusses the behavior of Candida among immunocompromised men, the presence and diagnosis of Candida infections, treatment options for Candida infections by clinicians, and the risks that can be mitigated and sexual wellness maintained by patients and their partners.

Male Yeast Infections: What You Need to Know

Candida species are normal members of the mucosal microbiota and human skin.

Candida may get out of balance and produce symptoms when the balance of microbes or host defenses is altered.1

This is usually manifested on the penis as:

  • Redness
  • Itching
  • A burning sensation

It consists sometimes of small patches of white or of a lumpy discharge beneath the foreskin.10

Uncircumcised men and men with large local moisture have higher chances of developing balanitis since the warm and moist place supports the growth of yeast.2

Other triggers seen among healthy men are:

  • Recent antibiotic use
  • Poor local hygiene
  • High blood sugar levels1,9

The same organism can lead to repeated occurrences more often in immunocompromised individuals and be spread outside the genital area in case the immune system fails to contain the fungal growth.1,3

The concept of Candida being generally a harmless commensal that only causes problems once host defenses change is likely to lower the shame levels and promote early treatment.

The reason is that immunocompromised men are more vulnerable (HIV, chemotherapy).

Normally, the immune system keeps Candida growth in check.

Candida takes its toll when the body is weakened in terms of immunity.

In people with HIV:

Reduced CD4 T lymphocyte levels are associated with an increase in the prevalence of mucocutaneous candidiasis and oral and genital diseases.3

Genital disease in HIV-positive people resembles other cases in immunosuppressed individuals, but is more prevalent and recurrent with an increased amount of immunosuppression.3

In men on chemotherapy:

Neutropenia and destruction of mucosal barriers can be caused by cytotoxic chemotherapy.

It can also change the normal microbiome, which competes with Candida.

Antifungal prophylaxis is advised in high-risk patients during long or deep neutropenia due to the high morbidity and mortality of systemic fungal disease under antifungal prophylaxis.4

Men receiving chemotherapy may experience it even when the infections are localized to the penis.

  • More severe symptoms
  • Slower healing
  • Higher risk of recurrence

Clinicians who work with HIV and oncology populations should not only pay attention to Candida as a superficial nuisance but also as an indication of strained host defenses and the possibility of the need to manage it on a larger scale.

Clinical Findings and Symptoms

In immunocompetent men, candidal balanitis is usually characterized by:

  • Redness of the glans
  • The presence of itch, burning, and soreness.
  • A whitish, scurf-like discharge underneath your foreskin (in men who are not circumcised)10,2

Those symptoms in immunocompromised patients are:

  • More intense
  • More persistent

Extreme inflammation may result in:

  • Fissures
  • Painful urination
  • The inability to retract the foreskin2,8

The clinicians also seek evidence of spread, which includes:

Treatment-resistant or recurrent genital candidiasis in a person who seems healthy should initiate assessment of immunosuppression underlying the infection, such as HIV testing or blood sugar levels to determine diabetes.1,3

Notably, an indication of systemic vulnerability rather than a local skin issue can be severe or persistent candidiasis.

Diagnosis and Medical Evaluation

Diagnosis begins with:

  • A focused medical history
  • A critical examination of the genitals

A conspicuous white spot or inflamed glans can be sufficient to initiate therapy, though lab tests assist in the confirmation of Candida and the elimination of other conditions that include:

  • Bacterial balanitis
  • Sexually transmitted diseases

Swabs may be forwarded to microscopy, culture, or molecular when:

  • The diagnosis is unclear
  • Normal therapy does not work against infections1,8

Clinicians regularly:

  • Check for oral concomitant infection (e.g., oral thrush)
  • Assess immune status

In the case of patients under chemotherapy, this involves the following review:

Recurrent candidiasis should raise the suspicion of testing in those with an unknown immunological status. Such as: 

  • HIV
  • Diabetes
  • Other immunosuppressive disorders3,8

Treatment Options

Topical azole antifungals, including clotrimazole, are used as first-line treatment of localized penile candidiasis.

Their application lasts 1 to 2 weeks and works in most cases without complications.5,10

In case of acute or persistent infection:

Fluconazole may be prescribed as one oral dose or an oral short course.

Clinicians need to consider the interactions of drugs and immune status in selecting systemic therapy.5,8

In immunocompromised patients:

The treatment might require more interventions to deal with underlying immunosuppression.

In the case of HIV patients, it is important to maximize antiretroviral therapy (ART) to minimize recurrence.3

Antifungal prophylaxis or systemic agents can be employed in the case of those undergoing chemotherapy according to IDSA or ASCO guidelines.4,6

In case of treatment failure, physicians can conduct culture and susceptibility testing to offer treatment advice.8

Adjunct care includes:

  • Maintenance of the area to be clean and dry
  • Staying away from perfumed soaps and irritants
  • Putting on breathable underclothes
  • Abstinence during symptomatic periods to alleviate pain and reinfection10,5

Preventive Strategies

Immunocompromised men can be prevented through daily care and medical care.

Simple steps include:

  • Light sponging using water and drying.
  • Having loosely fitting cotton underwear.
  • Use of noxious or scented topical products in the avoidance of perfumed products10

Key preventive measures:

  • Controlling diabetes
  • Optimizing HIV therapy3,9
  • Prophylaxis with antifungal agents in the case of expected prolonged neutropenia in chemotherapy4,6
  • Maximum attention to preventive antibiotics to preserve protective bacterial flora9

In case the infections still recur after these measures, the clinicians would consider resistant Candida species or underlying conditions.

Sexual Health and Relationships

Sex can be painful with symptoms that result in decreased libido and strained relationships.

These disruptions are more debilitating in immunocompromised men due to frequent or protracted episodes of disruption.

Recurrent genital candidiasis has been reported to affect mental health and relationships, with a 2023 study demonstrating that candidal balanoposthitis is also associated with sexual dysfunction and emotional distress.7

Partners may:

  • Feel confused or anxious
  • Canada misunderstands withdrawal as disinterest.

This is the reason why it is crucial to communicate openly and co-evaluate medicine.

Clinicians are encouraged to speak freely about sexual health, and the couple can have their issues addressed by making temporary changes to intimacy during the course of treatment.

FAQs

Can an HIV positive man transmit Candida to a partner?

Yes, Candida can be transmitted through sex in case of active infection. Nevertheless, it is not regarded as a classic STI. Treatment of the couple helps minimize re-infection.6,5

Does ART failure manifest itself through genital candidiasis?

Not necessarily. However, frequent or extreme instances may point to the inability to keep immune control, which is why CD4 count and ART adherence ought to be monitored.3

Is antifungal prophylaxis administerable to chemotherapy patients?

Yes. Antifungal prophylaxis is commonly advised to patients who are anticipated to have long-term neutropenia, based on the condition.4,6

When am I going to be able to have sex again? 

This should be done after symptoms and inflammation have subsided and treatment is initiated to avoid pain and reinfection.5,10 

When should I see a doctor? 

In case of the persistence of symptoms over two weeks, regular occurrence, or extreme, visit a medical practitioner. Whenever there is recurrent infection, it should be followed by an examination of immunosuppression.1,3

Summary

Candida infections are more common and difficult to cure in men with compromised immunity caused by HIV or chemotherapy.

The best approach combines:

  • Prompt antifungal therapy
  • Monitoring immune health
  • Practical self-care
  • Candid communication with partners.

You should visit your care team early in case you are immunocompromised and you have recurrent or severe symptoms in your genitals.

Preventive measures in the form of treatment of the infection and the immune health also contribute to the prevention of complications and the improvement of physical and emotional health.

References

  1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev. 2010 Apr;23(2):253-73. Accessed 2025 Oct 10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2863365/
  2. Wray A. Balanitis. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Aug 31. Accessed 2025 Oct 10. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537143/
  3. US Department of Health and Human Services. Candidiasis. In: Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. ClinicalInfo HIV. Updated Sep 16, 2024. Accessed 2025 Oct 10. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infections/candidiasis
  4. Taplitz RA, et al. Antimicrobial prophylaxis for adult patients with cancer receiving chemotherapy. J Clin Oncol. 2018;36(11):1146-1157. (ASCO/IDSA guideline summary). Accessed 2025 Oct 10. Available from: https://pubmed.ncbi.nlm.nih.gov/30179565/
  5. Centers for Disease Control and Prevention. Treatment of Candidiasis. Candidiasis. CDC. Updated Apr 24, 2024. Accessed 2025 Oct 10. Available from: https://www.cdc.gov/candidiasis/treatment/index.html
  6. David LM, Walzman M, Rajamanoharan S. Genital colonisation and infection with Candida in heterosexual and homosexual males. Genitourin Med. 1997 Oct;73(5):394-6. Accessed 2025 Oct 10. Available from: https://pubmed.ncbi.nlm.nih.gov/9534752/
  7. Dhillon SS, Dhaliwal R, Dev K, Mehmi N. Sexual Dysfunction Evaluation in Candidal Balanoposthitis: A Single Centred Observational Study. J Family Reprod Health. 2023;17(1):8-13. Accessed 2025 Oct 10. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10394488/
  8. Pappas PG, et al. Candidiasis: Practice Essentials. In: Medscape. Updated Sep 27, 2024. Accessed 2025 Oct 10. Available from: https://emedicine.medscape.com/article/213853-overview
  9. Li H, et al. Interactions between Candida albicans and the resident microbiota. Front Microbiol. 2022;13:930495. doi:10.3389/fmicb.2022.930495. Accessed 2025 Oct 10. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2022.930495/full
  10. Cleveland Clinic. Male Yeast Infection (Candida Balanitis): Symptoms, Causes. Cleveland Clinic. Published 2023. Accessed 2025 Oct 10. Available from: https://my.clevelandclinic.org/health/diseases/23199-male-yeast-infection
Share

Ekomobong Sunday

Pharm.D (In View), University of Uyo, Nigeria

Ekomobong is a passionate Health Writer with a background in Pharmacy and a focus on male and female fertility, pregnancy, motherhood, and childcare. He simplifies complex medical information into engaging and relatable content for both professionals and everyday readers alike. Beyond writing, he’s committed to bridging the gap between science and the public through engaging storytelling and trusted health communication.

arrow-right